

Our Commitment to Transparency

Our commitment to transparency is fundamental to our mission of transforming mental healthcare. As a public benefit corporation, we focus on delivering a positive impact to the people we work with, our employees and the patients we hope to help. We recognize the importance of fostering trust and accountability among all stakeholders, including patients, healthcare professionals and the broader global community.

What is open science?

Open science is defined as the principle and practice of making research products, documentation and processes available to all, while respecting diverse cultures, maintaining security and privacy, and fostering collaborations, reproducibility and equity.¹

As outlined in <u>our tenets of public benefit</u>—and in line with <u>our values</u> of openness, impact, integrity and care—our goal is to have a transparent, open science approach to how we conduct our business, research, drug development and commercialization to positively support innovations for patients.

We believe in the meaningful benefits of open science—the wide and free sharing of research, data, samples, software, ideas and results—for many reasons, including the ability to:

- Increase access to our data to spur additional research and advance potential new investigational psychedelic treatments;
- Promote greater community support for and participation in scientific advancements;
- · Help make scientific findings more broadly accessible; and
- Increase productivity and encourage peer review of results.

Our transparency policy is designed to uphold the highest standards in knowledge-sharing by:

- Publishing clinical trial results and ensuring top-line results are summarized and shared with the general public, including trial participants, advocates and others;
- Sharing information, such as formal regulatory communications and outcomes from key discussions related to our clinical development program, with the research community;
- Providing clear information regarding our compliant approach to pricing, reimbursement and patient assistance
 programs including methodology intended to make treatment innovations available and accessible to those who
 need them;
- **Disclosing business operation practices** regarding our corporate governance structure, policies and financial performance to maintain clear lines of communication with our employees, the psychedelic ecosystem and regulatory bodies to foster trust and accountability; and
- Communicating our approach and any developments related to intellectual property rights, recognizing the delicate balance between fostering innovation and promoting broader access to medical advancements.

It is important to acknowledge that certain factors may impact our ability to share information including legal parameters, regulatory requirements, financial risks, ethical considerations and resource constraints. We are committed to regularly evaluating these factors as we continue to deliver long-term value to the research community to accelerate the discovery and development of new investigational treatments that are accessible, affordable and impactful if approved by the FDA in the mental healthcare space.